KAMADA » MEDIA » NEWS

NEWS


Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

Press Release / Jun. 4, 2018

The results from the Company’s Phase 2 trial of Alpha-1 Antitrypsin (AAT) in newly diagnosed type-1 diabetes (T1D) will be presented in an oral session at the 78th Scientific Sessions of the American Diabetes Association (ADA).

Kamada Reports Financial Results for First Quarter of 2018

Press Release / May. 15, 2018

Kamada today announced financial results for the three months ended
March 31, 2018.

Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

Press Release / May. 8, 2018

KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches.

Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Press Release / Apr. 24, 2018

Kamada announced that the company recently received feedback from the U.S. Food and Drug Administration (FDA) regarding the proposed pivotal Phase 3 protocol for its proprietary Inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

Press Release / Feb. 7, 2018

Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017.

Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

Press Release / Jan. 4, 2018

Kamada announced a collaboration with the Mount Sinai Acute GvHD International Consortium (MAGIC) to conduct a proof-of-concept clinical trial assessing the safety and preliminary efficacy of Kamada’s Alpha- 1-Antitrypsin (AAT) as preemptive therapy for patients at high-risk for the development of steroidrefractory acute GvHD (SR-aGvHD).

Kamada and Chiesi Farmaceutici S.p.A. Mutually Agree to Terminate European Distribution Agreement for Inhaled Alpha-1 Antitrypsin Therapy for Treatment of Alpha-1 Antitrypsin Deficiency

Press Release / Nov. 22, 2017

Kamada announced that the Company and Chiesi Farmaceutici S.p.A., a fully integrated European Pharmaceutical company focused on respiratory disease and special care products, have mutually agreed to terminate the parties’ European distribution agreement related to Kamada’s inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

Kamada Announces New Supply Agreement with International Organization for KamRAB for Post-Exposure Prophylaxis Against Rabies Infection

Press Release / Nov. 21, 2017

Kamada announced today that it has signed a supply agreement with an undisclosed international organization for KamRAB [rabies immune globulin (Human)].  

Amended Notice of 2017 Annual General Meeting of Shareholders

Press Release / Nov. 10, 2017

On October 26, 2017, Kamada Ltd. announced the 2017 Annual General Meeting of shareholders of the Company to be held on November 30, 2017.

 

Kamada to Announce Third Quarter 2017 Financial Results and Host Conference Call on November 13

Press Release / Nov. 8, 2017

Kamada announced today that it will release financial results for the third quarter ended September 30, 2017, prior to the open of the U.S. financial markets on Monday, November 13.

out of 11 items.